Spectrum Pharmaceuticals, Inc. Reports Record Revenues, Profits, and Cash Generated from Operations for the Twelve-Month Period Ended December 31, 2011

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI):

Financial Highlights: HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI):

First Full Year of Profitability Since Inception in 2002 Total Revenues of $193 Million in 2011, Up 160% From Previous Record Revenues of $74 Million in 2010, Comprised of Product Sales of $181 Million: $153 Million From FUSILEV $28 Million From ZEVALIN